8 results
The primary objective of this study is to determine if neuroinflammation is present in patients with mild traumatic brain injury, using [11C]-PK11195 PET. The secondary objective is to determine if there is a correlation between [11C]-PK11195…
PrimaryTo evaluate the pharmacokinetics of two different tablet formulations of BCI-952 compared to the over-encapsulated BCI-952 product components.SecondaryTo evaluate the safety and tolerability following the administration of two different…
The primary objective is to determine whether neuroinflammation is present in subjects who have been exposed to chronic repetitive head injury during Muay Thai boxing, using [11C]-PK11195 PET.
Primary Objective:The primary objective is to determine the safety, tolerability, dose-limiting toxicities (DLTs), and MTD/MAD/alternate dose of BMS-986156 administered alone and in combination with nivolumab in subjects with advanced solid tumors.…
The primary objective is to determine the safety, tolerability, dose-limiting toxicities (DLTs), and maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) of BMS-986178 administered alone or in combination with nivolumab and/or ipilimumab in…
Primary ObjectivesThe primary objectives for this study are as follows:* To evaluate the safety and tolerability of atezolizumab and ipilimumab when administered in combination in patients with advanced or metastatic non-small cell lung cancer (…
The primary objective is to determine the safety, tolerability, dose-limiting toxicities (DLTs), and maximum tolerated dose (MTD) of BMS-986016 administered alone and in combination with nivolumab in subjects with advanced solid tumors.The co-…
Primary objectivePhase I: To determine the recommended phase II dose (RP2D) of the combination treatment with nivolumab and entinostat administered to adolescents 12-21 years with progressive, relapsed , refractory high-risk solid tumors and CNS…